AIM
KYMR icon

AXA Investment Managers’s Kymera Therapeutics KYMR Stock Holding History

AXA Investment Managers’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.56M Buy
+80,534
New +$3.63M 0.01% 594

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

AXA Investment Managers's KYMR Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Kymera Therapeutics (KYMR) in Q3 2025: 80,534 shares worth $4.56M. The stake represents 0.01% of the portfolio and ranks #594 among its holdings.

210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • AXA Investment Managers held 80,534 shares of Kymera Therapeutics worth $4.56M as of Q3 2025.
  • Kymera Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • Kymera Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #594 holding.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.